Methylnaltrexone in Palliative Care: Further Research Is Needed

In this update, the conclusions for naldemedine are new. There is moderate-quality evidence to suggest that, taken orally, naldemedine improves bowel function over two weeks in people with cancer and OIBD but increases the risk of adverse events. The conclusions on naloxone and methylnaltrexone have not changed. The trials on naloxone did not assess laxation at 24 hours or over two weeks. There is moderate-quality evidence that methylnaltrexone improves bowel function in people receiving palliative care in the short term and over two weeks, and low-quality evidence that it does not increase adverse events. There is a need for more trials including more evaluation of adverse events. None of the current trials evaluated effects in children.

show abstract

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Candy

Jones

Vickerstaff

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Candy

Jones

Vickerstaff

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Advancing research into symptoms of constipation at the end of life

Clark

Currow²

2014

Int J Palliat Nurs

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Methylnaltrexone in Palliative Care: Further Research Is Needed

Cited by 3 publications

References 8 publications

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Advancing research into symptoms of constipation at the end of life

Contact Info

Product

Resources

About